21 June 2021 | News
Constructions of new facilities for ATMP formulation development up to biosafety level S2 are in progress and operations are expected to start by Q4 of 2021
Germany-based Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, announced the expansion of its ATMP development facilities under biosafety level S2 (BSL2 / S2).
Re-construction of an existing building near the Coriolis headquarters has started in March this year and the laboratories are planned to be operational in Q4 2021. The new facilities will increase Coriolis’ total floor space to 7,800 sq metre. The new labs will host the formulation development of ATMPs, cell culture activities, particle characterisation and identification, analytical ultracentrifugation and a lyophilisation development centre for ATMPs.
“Already in 2018, we started strengthening our scientific expertise and offering services for ATMPs and are now pleased to see that this segment experiences a significant growth,” says Dr Michael Wiggenhorn, CEO, Coriolis Pharma. “That is why we are expanding our capacities in this area with new lab facilities under biosafety level S2.”
“To support the lab expansion also from a scientific perspective, we recently expanded our Scientific Advisory Board by two distinguished experts in the field: Prof Ernst Wagner from the Ludwig-Maximilians-Universität (LMU) Munich and Prof. Gideon Kersten from the Leiden University,” explained Dr Andrea Hawe, CSO, Coriolis Pharma. “Their scientific advice will be valuable to the success of our client projects and will enable us to stay on top of the recent development in the field.”